SUPERNUS PHARMACEUTICALS, INC. Net Income (Loss) Available to Common Stockholders, Basic
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Net Income (Loss) Available to Common Stockholders, Basic of -$58.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-03
- SUPERNUS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$58.37M, a 359.44% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$2.29M.
- SUPERNUS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-06-30 was $22.50M, a 12.97% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-03-31 was -$11.83M, a 9637.90% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2025 was -$38.55M, a 152.19% decline from fiscal 2024.
- SUPERNUS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2024 was $73.86M, a 5512.84% increase from fiscal 2023.
- SUPERNUS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was $1.32M, a 97.95% decline from fiscal 2022.
- SUPERNUS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2022 was $64.27M, a 20.30% increase from fiscal 2021.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$58.37M 10-Q · filed 2026-08-03 | -$60.66M 10-Q · filed 2026-08-03 | |||||
| 2026-03-31 | -$2.29M 10-Q · filed 2026-05-05 | ||||||
| 2025-12-31 | -$38.55M 10-K · filed 2026-03-02 | ||||||
| 2025-06-30 | $22.50M 10-Q · filed 2026-08-03 | $10.67M 10-Q · filed 2026-08-03 | |||||
| 2025-03-31 | -$11.83M 10-Q · filed 2026-05-05 | ||||||
| 2024-12-31 | $73.86M 10-K · filed 2026-03-02 | ||||||
| 2024-06-30 | $19.92M 10-Q · filed 2024-08-06 | $20.04M 10-Q · filed 2024-08-06 | $21.21M derived: sum of 3 quarters · filed 2026-03-02 | $5.24M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-03-31 | $124.00K 10-Q · filed 2024-05-08 | $1.30M derived: sum of 2 quarters · filed 2026-03-02 | -$14.68M derived: sum of 3 quarters · filed 2026-03-02 | -$15.51M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2023-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$14.80M derived: sum of 2 quarters · filed 2026-03-02 | -$15.63M derived: sum of 3 quarters · filed 2026-03-02 | $1.32M 10-K · filed 2026-03-02 | |||
| 2023-09-30 | -$15.98M 10-Q · filed 2023-11-08 | -$16.81M derived: sum of 2 quarters · filed 2024-08-06 | $141.00K 10-Q · filed 2023-11-08 | $27.41M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2023-06-30 | -$831.00K 10-Q · filed 2024-08-06 | $17.01M 10-Q · filed 2024-08-06 | $43.38M derived: sum of 3 quarters · filed 2025-02-25 | $45.13M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2023-03-31 | $17.84M 10-Q · filed 2024-05-08 | $44.21M derived: sum of 2 quarters · filed 2025-02-25 | $45.96M derived: sum of 3 quarters · filed 2025-02-25 | $54.72M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2022-12-31 | $26.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $28.12M derived: sum of 2 quarters · filed 2025-02-25 | $36.88M derived: sum of 3 quarters · filed 2025-02-25 | $64.27M 10-K · filed 2025-02-25 | |||
| 2022-09-30 | $1.75M 10-Q · filed 2023-11-08 | $10.50M derived: sum of 2 quarters · filed 2023-11-08 | $37.89M 10-Q · filed 2023-11-08 | $39.45M derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-06-30 | $8.75M 10-Q · filed 2023-08-08 | $35.26M 10-Q · filed 2023-08-08 | $37.70M derived: sum of 3 quarters · filed 2023-08-08 | $59.26M derived: sum of 4 quarters · filed 2023-08-08 | |||
| 2022-03-31 | $26.50M 10-Q · filed 2023-05-09 | $28.95M derived: sum of 2 quarters · filed 2023-05-09 | $50.51M derived: sum of 3 quarters · filed 2023-05-09 | $74.23M derived: sum of 4 quarters · filed 2023-05-09 | |||
| 2021-12-31 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $24.00M derived: sum of 2 quarters · filed 2023-03-09 | $47.73M derived: sum of 3 quarters · filed 2023-03-09 | $53.42M 10-K · filed 2023-03-09 | |||
| 2021-09-30 | $21.56M 10-Q · filed 2022-11-09 | $45.29M derived: sum of 2 quarters · filed 2022-11-09 | $50.98M 10-Q · filed 2022-11-09 | $81.75M derived: sum of 4 quarters · filed 2023-03-09 | |||
| 2021-06-30 | $23.73M 10-Q · filed 2022-08-08 | $29.42M 10-Q · filed 2022-08-08 | $60.19M derived: sum of 3 quarters · filed 2023-03-09 | $100.19M derived: sum of 4 quarters · filed 2023-03-09 | |||
| 2021-03-31 | $5.69M 10-Q · filed 2022-05-12 | $36.46M derived: sum of 2 quarters · filed 2023-03-09 | $76.46M derived: sum of 3 quarters · filed 2023-03-09 | $111.13M derived: sum of 4 quarters · filed 2023-03-09 | |||
| 2020-12-31 | $30.77M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $70.77M derived: sum of 2 quarters · filed 2023-03-09 | $105.43M derived: sum of 3 quarters · filed 2023-03-09 | $126.95M 10-K · filed 2023-03-09 | |||
| 2020-09-30 | $40.00M 10-Q · filed 2021-11-05 | $74.66M derived: sum of 2 quarters · filed 2021-11-05 | $96.18M 10-Q · filed 2021-11-05 | ||||
| 2020-06-30 | $34.67M 10-Q · filed 2021-08-06 | $56.19M 10-Q · filed 2021-08-06 | |||||
| 2020-03-31 | $21.52M 10-Q · filed 2021-05-07 | ||||||
| 2019-12-31 | $113.06M 10-K · filed 2022-04-13 | ||||||
| 2018-12-31 | $25.89M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $53.90M derived: sum of 2 quarters · filed 2021-03-08 | $84.64M derived: sum of 3 quarters · filed 2021-03-08 | $110.99M 10-K · filed 2021-03-08 | |||
| 2018-09-30 | $28.01M 10-Q · filed 2018-11-09 | $58.75M derived: sum of 2 quarters · filed 2018-11-09 | $85.10M 10-Q · filed 2018-11-09 | $98.76M derived: sum of 4 quarters · filed 2020-02-28 | |||
| 2018-06-30 | $30.74M 10-Q · filed 2018-08-09 | $57.09M 10-Q · filed 2018-08-09 | $70.75M derived: sum of 3 quarters · filed 2020-02-28 | $86.71M derived: sum of 4 quarters · filed 2020-02-28 | |||
| 2018-03-31 | $26.35M 10-Q · filed 2018-05-10 | $40.01M derived: sum of 2 quarters · filed 2020-02-28 | $55.97M derived: sum of 3 quarters · filed 2020-02-28 | $73.34M derived: sum of 4 quarters · filed 2020-02-28 | |||
| 2017-12-31 | $13.66M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $29.62M derived: sum of 2 quarters · filed 2020-02-28 | $46.99M derived: sum of 3 quarters · filed 2020-02-28 | $57.28M 10-K · filed 2020-02-28 | |||
| 2017-09-30 | $15.96M 10-Q · filed 2018-11-09 | $33.33M derived: sum of 2 quarters · filed 2018-11-09 | $43.63M 10-Q · filed 2018-11-09 | $57.95M derived: sum of 4 quarters · filed 2019-03-01 | |||
| 2017-06-30 | $17.37M 10-Q · filed 2018-08-09 | $27.66M 10-Q · filed 2018-08-09 | $41.98M derived: sum of 3 quarters · filed 2019-03-01 | $103.81M derived: sum of 4 quarters · filed 2019-03-01 | |||
| 2017-03-31 | $10.30M 10-Q · filed 2018-05-10 | $24.62M derived: sum of 2 quarters · filed 2019-03-01 | $86.44M derived: sum of 3 quarters · filed 2019-03-01 | $96.69M derived: sum of 4 quarters · filed 2019-03-01 | |||
| 2016-12-31 | $14.32M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $76.14M derived: sum of 2 quarters · filed 2019-03-01 | $86.40M derived: sum of 3 quarters · filed 2019-03-01 | $91.22M 10-K · filed 2019-03-01 | |||
| 2016-09-30 | $61.83M 10-Q · filed 2017-11-09 | $72.08M derived: sum of 2 quarters · filed 2017-11-09 | $76.90M 10-Q · filed 2017-11-09 | $83.75M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2016-06-30 | $10.25M 10-Q · filed 2017-08-03 | $10.02M 10-Q · filed 2016-08-05 | $15.08M 10-Q · filed 2017-08-03 | $15.01M 10-Q · filed 2016-08-05 | $21.93M derived: sum of 3 quarters · filed 2018-03-01 | $25.84M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-03-31 | $4.83M 10-Q · filed 2017-05-09 | $4.99M 10-Q · filed 2016-05-10 | $11.68M derived: sum of 2 quarters · filed 2018-03-01 | $15.59M derived: sum of 3 quarters · filed 2018-03-01 | $18.03M derived: sum of 4 quarters · filed 2018-03-01 | ||
| 2015-12-31 | $6.85M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $10.77M derived: sum of 2 quarters · filed 2018-03-01 | $13.21M derived: sum of 3 quarters · filed 2018-03-01 | $13.94M 10-K · filed 2018-03-01 | $14.02M 10-K · filed 2016-03-09 | ||
| 2015-09-30 | $3.92M 10-Q · filed 2017-01-20 | $6.35M derived: sum of 2 quarters · filed 2017-01-23 | $7.09M 10-Q · filed 2017-01-20 | ||||
| 2015-06-30 | $2.44M 10-Q/A · filed 2017-01-23 | $2.00M 10-Q · filed 2016-08-05 | $3.18M 10-Q/A · filed 2017-01-23 | $2.92M 10-Q · filed 2016-08-05 | |||
| 2015-03-31 | $738.00K 10-Q/A · filed 2017-01-20 | $917.00K 10-Q · filed 2016-05-10 | |||||
| 2014-12-31 | -$10.93M 10-K · filed 2017-03-16 | $19.87M 10-K · filed 2015-03-12 | |||||
| 2013-12-31 | -$22.41M derived: 10-K/A 12 month − 10-Q 9 month · filed 2017-01-20 | -$46.50M derived: sum of 2 quarters · filed 2017-01-20 | -$73.86M derived: sum of 3 quarters · filed 2017-01-20 | -$92.27M 10-K/A · filed 2017-01-20 | |||
| 2013-09-30 | -$24.10M 10-Q · filed 2013-11-13 | -$51.45M derived: sum of 2 quarters · filed 2013-11-13 | -$69.87M 10-Q · filed 2013-11-13 | -$83.38M derived: sum of 4 quarters · filed 2015-03-12 | |||
| 2013-06-30 | -$27.36M 10-Q · filed 2013-08-14 | -$45.77M 10-Q · filed 2013-08-14 | -$59.28M derived: sum of 3 quarters · filed 2015-03-12 | -$72.77M derived: sum of 4 quarters · filed 2015-03-12 | |||
| 2013-03-31 | -$18.41M 10-Q · filed 2013-05-15 | -$31.93M derived: sum of 2 quarters · filed 2015-03-12 | -$45.41M derived: sum of 3 quarters · filed 2015-03-12 | -$55.71M derived: sum of 4 quarters · filed 2015-03-12 | |||
| 2012-12-31 | -$13.51M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | -$27.00M derived: sum of 2 quarters · filed 2015-03-12 | -$37.29M derived: sum of 3 quarters · filed 2015-03-12 | -$47.43M 10-K · filed 2015-03-12 | |||
| 2012-09-30 | -$13.48M 10-Q · filed 2013-11-13 | -$23.78M derived: sum of 2 quarters · filed 2013-11-13 | -$33.91M 10-Q · filed 2013-11-13 | $47.20M derived: sum of 4 quarters · filed 2014-03-21 | |||
| 2012-06-30 | -$10.30M 10-Q · filed 2013-08-14 | -$20.43M 10-Q · filed 2013-08-14 | $60.68M derived: sum of 3 quarters · filed 2014-03-21 | $50.09M derived: sum of 4 quarters · filed 2014-03-21 | |||
| 2012-03-31 | -$10.13M 10-Q · filed 2013-05-15 | $70.98M derived: sum of 2 quarters · filed 2014-03-21 | $60.39M derived: sum of 3 quarters · filed 2014-03-21 | $52.16M derived: sum of 4 quarters · filed 2014-03-21 | |||
| 2011-12-31 | $81.12M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | $70.53M derived: sum of 2 quarters · filed 2014-03-21 | $62.29M derived: sum of 3 quarters · filed 2014-03-21 | $50.38M 10-K · filed 2014-03-21 | |||
| 2011-09-30 | -$10.59M 10-Q · filed 2012-11-02 | -$18.83M derived: sum of 2 quarters · filed 2012-11-02 | -$30.73M 10-Q · filed 2012-11-02 | ||||
| 2011-06-30 | -$8.23M 10-Q · filed 2012-08-13 | -$20.14M 10-Q · filed 2012-08-13 | |||||
| 2011-03-31 | -$11.91M 10-Q · filed 2012-06-08 | ||||||
| 2010-12-31 | -$41.89M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |